Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Ascletis Pharma Inc. (HKG: 1672) announced today the selection of its fixed-dose combination (FDC) of ASC48 (oral GIPR agonist) and ASC30 (oral GLP-1R agonist) for clinical development as a potential first-in-class oral obesity therapy. The ASC30_48 FDC is designed for “one pill, once daily” administration, with an Investigational New Drug (IND) application expected to be submitted to the US FDA in Q4 2026.

Development Milestone | Key Details

Drug Profile & Mechanism of Action

Molecular Components

• ASC48: Potential first-in-class oral small molecule GIPR (glucose-dependent insulinotropic polypeptide receptor) agonist
• ASC30: Oral small molecule GLP-1R (glucagon-like peptide-1 receptor) agonist
• Combination: Fixed-dose dual GIPR/GLP-1R targeting
• Innovation: First oral dual agonist combination in development

Proprietary Technology Platform

ASC48 was developed using Ascletis’ AI-structured-based drug discovery (AISBDD) technology:

• AI-Driven Design: Leveraged artificial intelligence for molecular optimization
• Structural Precision: Enhanced target specificity and pharmacokinetic properties
• Proprietary Platform: Differentiates from traditional high-throughput screening approaches

Preclinical Pharmacokinetic Profile

ASC48 demonstrated compelling drug-like properties supporting once-daily dosing:

• Oral Bioavailability: Excellent absorption following oral administration
• Drug Exposure: High systemic exposure levels achieved
• Half-life: Long elimination half-life suitable for once-daily regimen
• Dosing Convenience: Single tablet formulation enables patient compliance

Strategic Rationale & Market Opportunity

Obesity Treatment Landscape

• Market Size: Global obesity therapeutics market projected to exceed $100 billion by 2030
• Current Leaders: Injectable GLP-1/GIP dual agonists (e.g., tirzepatide) demonstrating superior efficacy
• Unmet Need: Oral alternatives to injectable therapies with comparable efficacy
• Patient Preference: Strong demand for needle-free administration options

Competitive Differentiation

The ASC30_48 FDC offers several potential advantages:

• First Oral Dual Agonist: Addresses significant gap vs. current injectable-only dual agonists
• Convenience Factor: “One pill, once daily” vs. weekly injections
• Cost Potential: Oral manufacturing typically less expensive than biologic production
• Accessibility: Broader patient access without injection requirements

AI-Driven Innovation

Ascletis’ AISBDD platform represents a next-generation drug discovery approach:

• Accelerated Development: AI-enabled molecular design reduces discovery timelines
• Enhanced Properties: Computational optimization of pharmacokinetic parameters
• Intellectual Property: Strong patent protection around AI-designed molecules
• Platform Validation: Success with ASC48 validates AISBDD for future pipeline candidates

Development Timeline & Regulatory Strategy

The company’s aggressive development timeline includes:

• Q4 2026: IND submission to US FDA
• 2027: Initiation of Phase 1 clinical trials
• 2028-2029: Phase 2 proof-of-concept studies
• 2030+: Potential Phase 3 development and regulatory submissions

This timeline positions Ascletis to potentially become the first company to market an oral dual GIPR/GLP-1R agonist, capitalizing on the massive commercial opportunity in obesity treatment while addressing key patient barriers to current therapies.

Strategic Implications

For Ascletis, the ASC30_48 FDC represents a transformative pipeline asset that could:

• Establish the company as a leader in oral metabolic disease therapeutics
• Generate significant licensing or partnership opportunities with major pharma
• Validate the AISBDD platform for broader application across therapeutic areas
• Create substantial shareholder value through clinical and regulatory milestones

The dual agonist approach leverages emerging scientific understanding that combined GIPR and GLP-1R activation provides superior weight loss efficacy compared to GLP-1R agonism alone, as demonstrated by the clinical success of injectable dual agonists.

Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory submissions, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech